Eli Lilly Reports Year-End 2025 Financial Results

SEC 8-K Filing Notice

Company: Eli Lilly and Company (LLY) Filing Date: 2026-02-04 Accession Number: 0000059478-26-000008

Items Filed

Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Summary

Eli Lilly and Company filed an 8-K on February 4, 2026, reporting its financial results for the quarter and year ended December 31, 2025. The filing includes a press release (Exhibit 99.1) detailing the company's performance. This information is crucial for investors and industry analysts to assess Lilly's financial health and operational effectiveness. The filing also lists the company's securities registered on the New York Stock Exchange, including various notes due between 2026 and 2061, providing insight into Lilly's capital structure.

Key Takeaways

Eli Lilly reported its financial results for Q4 and the full year 2025.
The report was furnished, not filed, meaning less legal liability but also less weight for certain purposes.
The filing includes a press release (Exhibit 99.1) with detailed financial information.
Lilly has multiple notes due between 2026 and 2061 listed on the NYSE.
Donald A. Zakrowski, Senior Vice President, Finance, and Chief Accounting Officer, signed the report.

Analysis

This 8-K filing provides investors with essential information to evaluate Eli Lilly's financial performance. The results will likely be scrutinized to determine if the company met expectations and if its growth trajectory remains positive. Competitors will analyze Lilly's performance to benchmark their own results and identify potential strategic advantages or disadvantages. The long-term notes listed indicate Lilly's ability to raise capital and its confidence in future revenue streams, likely tied to its pipeline and existing product portfolio. Any significant deviation from expectations could impact Lilly's stock price and investor confidence.

This post was automatically generated from an SEC 8-K filing.